NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies<
12 May 2022

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

Supported by encouraging preclinical and preliminary clinical data, we believe in the potential of LAVA-051 to address unmet patient needs.
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System<
10 May 2022

CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System

Heart failure patients implanted with Barostim can now receive conditional MRI scans
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference<
05 May 2022

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer
SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022<
05 May 2022

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022

demonstrating a highly significant protection of visual function as well as greater cone density following subretinal administration of SPVN06 in a murine model.
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®<
03 May 2022

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

Expands Commercial coverage to 92% of total commercial lives
SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022<
03 May 2022

SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022

SparingVision, will present pharmacology and safety data on its lead product SPVN06
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting<
03 May 2022

Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Preclinical studies support further development of AU-011 for choroidal metastasis

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference idal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting<
03 May 2022

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference idal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

A live webcast of the presentation will be available on Aura's “Investors & Media” page
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer<
03 May 2022

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules.
Xeltis’ clinical study with restorative hemodialysis access graft, aXess, shows promising early puncturing, patency and safety data<
27 Apr 2022

Xeltis’ clinical study with restorative hemodialysis access graft, aXess, shows promising early puncturing, patency and safety data

International pivotal trial expedited to potentially revolutionize hemodialysis treatment with an immediate and durable solution

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка